EGFR and cancer: According to research, which showed that EGFR activation in various cancer cell lines was α2-6 sialylation-dependent, ST6Gal-I OE in Suit2 cells increased α2-6 sialylation and basal EGFR activation, whereas ST6Gal-I KD in S2-013 and S2-LM7AA decreased EGFR sialylation and activation.